Pricing Transparency Policies Not Suited To Generics, GPhA Argues

Legislation like FAIR drug pricing bill, which requires sponsors to justify price increases over 10%, could ultimately discourage generic competition since it could burden ANDA sponsors for even small dollar increases, GPhA CEO Davis argues.